Regeneron Pharmaceuticals, Inc. Revenue 2008–2025
Regeneron Pharmaceuticals, Inc. annual/quarterly revenue history and growth rate from 2008 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Regeneron Pharmaceuticals, Inc. revenue for the quarter ending March 31, 2026 was 3.6 B, a 19.04% increase year-over-year.
- Regeneron Pharmaceuticals, Inc. revenue for the twelve months ending March 31, 2026 was 14.1 B, a 2.09% increase year-over-year.
- Regeneron Pharmaceuticals, Inc. annual revenue for 2025 was 14.3 B, a 0.99% increase from 2024.
- Regeneron Pharmaceuticals, Inc. annual revenue for 2024 was 14.2 B, a 8.27% increase from 2023.
- Regeneron Pharmaceuticals, Inc. annual revenue for 2023 was 13.1 B, a 7.76% increase from 2022.
- Regeneron Pharmaceuticals, Inc. annual revenue for 2022 was 12.2 B.
Regeneron Pharmaceuticals Inc. (REGN) — Frequently Asked Questions
Regeneron Pharmaceuticals Inc. (REGN) is a publicly traded US company in the Healthcare sector. It has a market capitalization of $65.34B. In fiscal 2025 it reported revenue of $14.34B and net income of $4.50B. Explore REGN's stock price, financial statements, earnings history, margins and key ratios below.
What is Regeneron Pharmaceuticals Inc.'s market cap?
Regeneron Pharmaceuticals Inc. (REGN) has a market capitalization of $65.34B.
What is the REGN stock price?
REGN trades at $601.65 (-2.36% on the day).
How much revenue does Regeneron Pharmaceuticals Inc. make?
Regeneron Pharmaceuticals Inc. reported revenue of $14.34B in fiscal 2025.
Is REGN profitable?
In fiscal 2025, Regeneron Pharmaceuticals Inc. reported net income of $4.50B.
What is REGN's P/E ratio?
Based on diluted EPS, REGN has a price-to-earnings (P/E) ratio of about 14.5.